Waters Corporation $WAT Position Reduced by Boston Trust Walden Corp

Boston Trust Walden Corp decreased its holdings in shares of Waters Corporation (NYSE:WAT) by 2.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 95,381 shares of the medical instruments supplier’s stock after selling 2,823 shares during the period. Boston Trust Walden Corp’s holdings in Waters were worth $41,909,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in WAT. Ashton Thomas Securities LLC grew its holdings in shares of Waters by 3.5% in the 3rd quarter. Ashton Thomas Securities LLC now owns 704 shares of the medical instruments supplier’s stock valued at $309,000 after acquiring an additional 24 shares in the last quarter. Caitlin John LLC increased its position in shares of Waters by 43.9% in the second quarter. Caitlin John LLC now owns 82 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 25 shares during the last quarter. Park Avenue Securities LLC increased its position in shares of Waters by 2.8% in the third quarter. Park Avenue Securities LLC now owns 910 shares of the medical instruments supplier’s stock valued at $400,000 after acquiring an additional 25 shares during the last quarter. Kingswood Wealth Advisors LLC raised its holdings in Waters by 3.7% during the third quarter. Kingswood Wealth Advisors LLC now owns 786 shares of the medical instruments supplier’s stock worth $345,000 after acquiring an additional 28 shares in the last quarter. Finally, Avalon Trust Co raised its holdings in Waters by 2.3% during the first quarter. Avalon Trust Co now owns 1,330 shares of the medical instruments supplier’s stock worth $396,000 after acquiring an additional 30 shares in the last quarter. Institutional investors own 94.01% of the company’s stock.

Waters Stock Up 1.8%

Shares of WAT opened at $467.99 on Thursday. Waters Corporation has a 52 week low of $282.77 and a 52 week high of $482.28. The stock has a market capitalization of $45.98 billion, a price-to-earnings ratio of 200.86, a PEG ratio of 2.67 and a beta of 1.16. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 0.66. The stock has a fifty day moving average of $433.18 and a 200-day moving average of $371.53.

Waters (NYSE:WAT) last posted its earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 EPS for the quarter, topping the consensus estimate of $4.00 by $0.10. Waters had a net margin of 1.75% and a return on equity of 9.91%. The business had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.75 billion. During the same period last year, the company earned $3.40 EPS. The firm’s revenue was up 120.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Waters Corporation will post 14.61 earnings per share for the current fiscal year.

Key Stories Impacting Waters

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Q3 results topped expectations. Waters reported adjusted EPS of $4.10 versus about $4.00 expected and revenue of $1.77 billion versus $1.75 billion expected. Organic revenue grew 9% (10% in constant currency); reported revenue growth of 120.9% also reflected acquisitions. Waters Q3 results
• Positive Sentiment: Management raised its 2026 outlook and outlined growth beyond this year. The earnings-call framework pointed to high-single-digit growth and a 29.2% adjusted operating margin for 2027, reinforcing expectations for continued expansion. Earnings call highlights
• Positive Sentiment: Analysts raised targets after the results. Citi raised its target to $536 and kept a Buy rating; TD Cowen and Barclays moved to $530, while RBC set $525. These revisions signal improved confidence in Waters’ prospects. Citi analyst actions
• Positive Sentiment: MOBILion Systems acquisition expands Waters’ proteomics capabilities. Its ion-mobility technology complements Waters’ mass-spectrometry platform and is aimed at research workflows that need faster, higher-resolution data. MOBILion acquisition announcement
• Neutral Sentiment: JPMorgan lifted its price target to $470 but retained a Neutral rating, indicating less near-term upside in its view. JPMorgan analyst action
• Negative Sentiment: Valuation may limit further gains: the supplied market data puts WAT’s P/E at 116.71, and recent commentary has questioned whether the shares already reflect the improved outlook. Waters valuation commentary

Wall Street Analysts Forecast Growth

WAT has been the topic of several recent analyst reports. Morgan Stanley set a $430.00 price target on Waters in a research report on Wednesday, August 5th. Robert W. Baird raised their target price on shares of Waters from $456.00 to $495.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Jefferies Financial Group boosted their price target on Waters from $450.00 to $455.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Stifel Nicolaus set a $470.00 price objective on shares of Waters in a research report on Wednesday. Finally, The Goldman Sachs Group boosted their price target on Waters from $465.00 to $515.00 and gave the company a “buy” rating in a research note on Monday, September 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $475.48.

Waters Profile

Waters Corporation (NYSE:WAT) develops and manufactures analytical technologies used to measure, identify and characterize chemical and biological substances. Its customers include pharmaceutical and biotechnology companies, industrial manufacturers, academic and government laboratories, and organizations involved in food, environmental and clinical testing.

The company’s product portfolio includes high-performance liquid chromatography and ultra-performance liquid chromatography systems, mass spectrometers, chromatography columns and consumables, and laboratory software for data management and analysis.